An integrated quantitative virological and immunological approach to optimise treatment and define correlates of immune protection against cytomegalovirus in allograft recipients. (360G-Wellcome-078332_Z_05_Z)
In a unique collaboration with transplant clinicians we have produced a paradigm shift in understanding the pathogenesis of HCMV infection. Specifically, we have shown that: a) this virus replicates with rapid dynamics; b) it causes disease in individuals once a critical threshold value of viral load has been reached in the blood; c) patients with rapid replication have a HCMV-specific CD8+ immune defect ("specific interferon gamma impairment; SIGI") which precedes the onset of viraemia. These novel findings will be taken forward in four ways: i) we will conduct randomised controlled trials to optimise treatment based on real time measurement of HCMVviral load; ii) we will determine if SIGI explains why some patients have a slow response to treatment; iii) we will determine if reinfection with a different strain of HCMV can induce SIGI; iv) we will systematically extend immunological studies to determine if other specific immune responses against additional HCMV proteins, restricted by class I and class II HLA molecules, also correlate with full control of HCMV replication.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 605793 |
Applicant Surname | Griffiths |
Approval Committee | Immunology and Infectious Disease Funding Committee |
Award Date | 2005-10-25T00:00:00+00:00 |
Financial Year | 2005/06 |
Grant Programme: Title | Programme Grant |
Internal ID | 078332/Z/05/Z |
Lead Applicant | Prof Paul Griffiths |
Other Applicant(s) | Prof Caroline Sabin, Prof Paul Klenerman, Prof Vincent Emery |
Partnership Value | 605793 |
Planned Dates: End Date | 2011-09-19T00:00:00+00:00 |
Planned Dates: Start Date | 2006-04-20T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |